NCT04113486Recruiting
Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-renal Cancer Populations
Source: ClinicalTrials.gov · Last updated 29 Jul 2026
Brief summary (registry, in English)
This study aims to observe the difference between NMAP (nicotinamide metabolism associated protein) serum levels in primary diagnosed renal cancer patients and non-renal cancer patient controls, plot the ROC curve and establish appropriate cut-off values.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 400 (estimated)
- First submitted
- 1 Oct 2019
- Start date
- 1 Oct 2019
- Primary completion date
- 30 Jan 2029
- Lead sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Diseases
- Kidney cancer
- NCT number
- NCT04113486
What you commit to
- Study type: Observational
- Planned participants: 400
- From 1 Oct 2019 to the primary completion date, 30 Jan 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- The investigators believe that the subject may be unsuitable for inclusion due to severe concurrent diseases, infections, and etc.
- Major surgery (surgery requiring general anesthesia) was performed within 4 weeks prior to screening visits.
Other illness
- The subjects is known or suspected of other malignancies.
- There has been another history of malignancy in the past 5 years.
Who the study is looking for
- The tumor group patients were found to have renal or hepatic mass, plan to receive surgical treatment (except for radiofrequency ablation, cryoablation, etc., which were not available for pathological examination). The control group patients were ruled out of tumor based on radiological tests and commonly used tumor biomarkers
- Age ≥ 18 years old and able to provide written informed consent;
- Have not received any systemic or topical treatment for kidney/liver tumors.
- Cardiopulmonary, liver and kidney functions are able to tolerate surgery and can comply with research requirements.
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.